Adaptimmune Therapeutics (ADAP) Competitors $0.66 -0.01 (-1.48%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ADAP vs. PGEN, CLLS, FATE, ATRA, BLUE, TRDA, ABUS, DNTH, CRMD, and TECXShould you be buying Adaptimmune Therapeutics stock or one of its competitors? The main competitors of Adaptimmune Therapeutics include Precigen (PGEN), Cellectis (CLLS), Fate Therapeutics (FATE), Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Entrada Therapeutics (TRDA), Arbutus Biopharma (ABUS), Dianthus Therapeutics (DNTH), CorMedix (CRMD), and Tectonic Therapeutic (TECX). These companies are all part of the "medical" sector. Adaptimmune Therapeutics vs. Precigen Cellectis Fate Therapeutics Atara Biotherapeutics bluebird bio Entrada Therapeutics Arbutus Biopharma Dianthus Therapeutics CorMedix Tectonic Therapeutic Adaptimmune Therapeutics (NASDAQ:ADAP) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, community ranking, media sentiment and institutional ownership. Does the MarketBeat Community believe in ADAP or PGEN? Precigen received 118 more outperform votes than Adaptimmune Therapeutics when rated by MarketBeat users. Likewise, 67.29% of users gave Precigen an outperform vote while only 62.95% of users gave Adaptimmune Therapeutics an outperform vote. CompanyUnderperformOutperformAdaptimmune TherapeuticsOutperform Votes31662.95% Underperform Votes18637.05% PrecigenOutperform Votes43467.29% Underperform Votes21132.71% Does the media refer more to ADAP or PGEN? In the previous week, Adaptimmune Therapeutics had 11 more articles in the media than Precigen. MarketBeat recorded 25 mentions for Adaptimmune Therapeutics and 14 mentions for Precigen. Adaptimmune Therapeutics' average media sentiment score of 0.43 beat Precigen's score of -0.01 indicating that Adaptimmune Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptimmune Therapeutics 3 Very Positive mention(s) 4 Positive mention(s) 4 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Precigen 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has more risk & volatility, ADAP or PGEN? Adaptimmune Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Comparatively, Precigen has a beta of 1.68, indicating that its share price is 68% more volatile than the S&P 500. Do insiders and institutionals have more ownership in ADAP or PGEN? 31.4% of Adaptimmune Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 12.4% of Adaptimmune Therapeutics shares are owned by company insiders. Comparatively, 44.9% of Precigen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has stronger earnings and valuation, ADAP or PGEN? Precigen has lower revenue, but higher earnings than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Precigen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptimmune Therapeutics$60.28M2.82-$113.87M-$0.22-3.02Precigen$6.22M39.40-$95.90M-$0.55-1.52 Do analysts rate ADAP or PGEN? Adaptimmune Therapeutics presently has a consensus price target of $3.16, indicating a potential upside of 375.78%. Precigen has a consensus price target of $7.00, indicating a potential upside of 736.62%. Given Precigen's higher possible upside, analysts clearly believe Precigen is more favorable than Adaptimmune Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptimmune Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Precigen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Is ADAP or PGEN more profitable? Adaptimmune Therapeutics has a net margin of -25.43% compared to Precigen's net margin of -3,521.68%. Adaptimmune Therapeutics' return on equity of -74.15% beat Precigen's return on equity.Company Net Margins Return on Equity Return on Assets Adaptimmune Therapeutics-25.43% -74.15% -15.09% Precigen -3,521.68%-123.06%-87.33% SummaryAdaptimmune Therapeutics beats Precigen on 9 of the 17 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Adaptimmune Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ADAP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADAP vs. The Competition Export to ExcelMetricAdaptimmune TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$170.08M$2.93B$5.06B$8.82BDividend YieldN/A1.89%5.18%4.07%P/E Ratio-3.0245.61126.3117.81Price / Sales2.82360.261,178.7474.57Price / CashN/A160.0933.8632.53Price / Book3.913.734.684.68Net Income-$113.87M-$41.63M$119.54M$226.08M7 Day Performance12.43%-4.73%-1.83%-1.04%1 Month Performance-19.31%-6.53%-3.60%1.04%1 Year Performance50.55%25.63%31.91%26.28% Adaptimmune Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADAPAdaptimmune Therapeutics2.1011 of 5 stars$0.66-1.5%$3.16+375.8%+54.9%$170.08M$60.28M-3.02449Analyst RevisionHigh Trading VolumePGENPrecigen3.7679 of 5 stars$0.84+5.0%$7.00+736.6%-30.9%$233.01M$6.22M0.00202Analyst RevisionCLLSCellectis2.468 of 5 stars$1.91-2.6%$7.00+266.5%-38.4%$106.16M$9.19M-1.47290Analyst ForecastFATEFate Therapeutics3.9121 of 5 stars$2.22+1.8%$6.75+204.1%-14.6%$252.84M$63.53M-1.35550Analyst UpgradeATRAAtara Biotherapeutics3.8122 of 5 stars$10.68-2.8%$16.67+56.1%-23.4%$61.52M$8.57M-0.41165BLUEbluebird bio2.8596 of 5 stars$0.30flat$3.03+898.3%-92.1%$58.92M$29.50M-0.17323Analyst ForecastTRDAEntrada Therapeutics1.9803 of 5 stars$17.93+0.9%$24.00+33.9%+9.9%$664.95M$129.01M11.28110ABUSArbutus Biopharma2.7966 of 5 stars$3.44-1.4%$5.50+59.9%+87.0%$661.33M$18.14M0.0073Analyst ForecastDNTHDianthus Therapeutics1.5021 of 5 stars$20.77-6.7%$46.43+123.5%+78.7%$659.12M$2.83M0.0080CRMDCorMedix2.6681 of 5 stars$10.74-3.0%$15.20+41.5%+184.1%$651.67M$12.26M-13.3230Insider TradeHigh Trading VolumeTECXTectonic Therapeutic3.5107 of 5 stars$44.03+7.8%$72.25+64.1%N/A$649.58MN/A-7.48120Analyst ForecastGap UpHigh Trading Volume Related Companies and Tools Related Companies PGEN Alternatives CLLS Alternatives FATE Alternatives ATRA Alternatives BLUE Alternatives TRDA Alternatives ABUS Alternatives DNTH Alternatives CRMD Alternatives TECX Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ADAP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
